88 related articles for article (PubMed ID: 35411336)
1. Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infection.
Oh CK; Nakamura T; Beutler N; Zhang X; Piña-Crespo J; Talantova M; Ghatak S; Trudler D; Carnevale LN; McKercher SR; Bakowski MA; Diedrich JK; Roberts AJ; Woods AK; Chi V; Gupta AK; Rosenfeld MA; Kearns FL; Casalino L; Shaabani N; Liu H; Wilson IA; Amaro RE; Burton DR; Yates JR; Becker C; Rogers TF; Chatterjee AK; Lipton SA
bioRxiv; 2022 Apr; ():. PubMed ID: 35411336
[TBL] [Abstract][Full Text] [Related]
2. Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection.
Oh CK; Nakamura T; Beutler N; Zhang X; Piña-Crespo J; Talantova M; Ghatak S; Trudler D; Carnevale LN; McKercher SR; Bakowski MA; Diedrich JK; Roberts AJ; Woods AK; Chi V; Gupta AK; Rosenfeld MA; Kearns FL; Casalino L; Shaabani N; Liu H; Wilson IA; Amaro RE; Burton DR; Yates JR; Becker C; Rogers TF; Chatterjee AK; Lipton SA
Nat Chem Biol; 2023 Mar; 19(3):275-283. PubMed ID: 36175661
[TBL] [Abstract][Full Text] [Related]
3. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
4. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
5. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
6. Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
Lapaillerie D; Charlier C; Guyonnet-Dupérat V; Murigneux E; Fernandes HS; Martins FG; Magalhães RP; Vieira TF; Richetta C; Subra F; Lebourgeois S; Charpentier C; Descamps D; Visseaux B; Weigel P; Favereaux A; Beauvineau C; Buron F; Teulade-Fichou MP; Routier S; Gallois-Montbrun S; Meertens L; Delelis O; Sousa SF; Parissi V
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0008322. PubMed ID: 35861550
[TBL] [Abstract][Full Text] [Related]
7. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
Basit A; Ali T; Rehman SU
J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
9. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
[TBL] [Abstract][Full Text] [Related]
10. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
[TBL] [Abstract][Full Text] [Related]
11. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
Nandi S; Roy H; Gummadi A; Saxena AK
Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
13. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms.
Xu B; Li G; Guo J; Ikezoe T; Kasirajan K; Zhao S; Dalman RL
J Vasc Surg; 2021 Nov; 74(5):1740-1751. PubMed ID: 33600934
[TBL] [Abstract][Full Text] [Related]
15. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection.
Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB
Front Immunol; 2022; 13():811430. PubMed ID: 35250984
[TBL] [Abstract][Full Text] [Related]
16. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
17. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
[TBL] [Abstract][Full Text] [Related]
18.
Ayyamperumal S; Jade D; Tallapaneni V; Chandrasekar MJN; Nanjan MJ
J Biomol Struct Dyn; 2022; 40(21):11383-11394. PubMed ID: 34455932
[TBL] [Abstract][Full Text] [Related]
19. The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.
Beddingfield BJ; Iwanaga N; Chapagain PP; Zheng W; Roy CJ; Hu TY; Kolls JK; Bix GJ
JACC Basic Transl Sci; 2021 Jan; 6(1):1-8. PubMed ID: 33102950
[TBL] [Abstract][Full Text] [Related]
20. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection
Curreli F; Victor SMB; Ahmed S; Drelich A; Tong X; Tseng CK; Hillyer CD; Debnath AK
mBio; 2020 Dec; 11(6):. PubMed ID: 33310780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
